Virtual screening of Alpha-Aminoadipate Aminotransferase inhibitors from FDA approved drugs for Glutaric Acidemia Type I (SSIEM 2026) - Aug 17, 2026 - Abstract #P-241; Pres time: Aug 26, 2026; 05:30 PM - 06:30 PM; Location: Hall 4&5; "Conclusion Among the evaluated compounds, lomitapide and pimozide emerged as the most promising candidates, exhibiting both sustained binding stability during molecular dynamics simulations and the most favorable binding free energies under the MM/GBSA model. Further experimental studies are required to evaluate the inhibitory activity and therapeutic potential of these compounds in biochemical and cellular models."
CNS Disorders • Metabolic Disorders
|
|
Akif Altun 1; Arzu Selamioğlu 1,2; Gülden Gökçay 1; Asuman Gedikbaşı 1
|